⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 1, 2025

Figure S1 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells

Soyoung Lee Kyunghwan Kim Hye‐Jin Jeong Subin Choi Himchan Cheng Dayoung Kim Soomin Heo Jinhee Mun Minjong Kim Eunjin Lee Yoon Ji Choi Seon‐gyeong Lee Eun A Lee Yewon Jang Kayeong Lim Heon Seok Kim Euihwan Jeong Seung‐Jae Myung Deok‐Beom Jung Chang Sik Yu In Ho Song M. Ryan Corces Joo H. Kang Kyungjae Myung Taejoon Kwon Tae‐Eun Park Jinmyoung Joo Seung Woo Cho

View Full Paper

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: Different delivery methods significantly affect CRISPR/Cas9-induced cell death in cancer cells.
KEY EVIDENCE: The study highlights variations in effectiveness based on sgRNA multiplexing strategies.
APPROACH: The analysis involved testing multiple delivery systems and evaluating their impact on cancer cell viability.
SIGNIFICANCE: This work provides insights for improving CRISPR-based therapies against cancer, enhancing treatment precision.

Implication

Figure S1 reveals how delivery methods and sgRNA multiplexing strategies influence cell death in cancer models, suggesting enhanced targeting.

Abstract

Figure S1 illustrates the impact of different delivery methods and sgRNA multiplexing strategies on CRISPR/Cas9-induced cell death.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0225 https://doi.org/10.1158/0008-5472.29760218

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S6 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells2025
2Figure S5 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells2025
3Figure S4 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells2025
4Figure S7 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells2025
5Figure S2 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells2025